FirstHealth of the Carolinas

Clinical Trial Details

Study Title: NOLAN: Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
Study Type: Interventional
Study Condition: Breast Cancer, Bone Pain
Investigator: Dr. Charles Kuzma
Phone: (910) 715-3500
Research Coordinator: Pam Mason
Phone: (910) 715-2200
Eligibility Criteria: Women ages 18 and older, newly diagnosed with Stage I-III breast cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Amgen
Study Rationale:
Study Purpose: In this study, the investigational products are naproxen, a non-steroidal antiinflammatory drug (NSAID), and loratadine, an anti-histamine. Both agents are being investigated as prophylactic medications to reduce the incidence and/or severity of bone pain in breast cancer subjects receiving adjuvant or neoadjuvant myelosuppressive chemotherapy and pegfilgrastim prophylaxis.
Study Link:
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.